
Acta Crystallographica, Section C: Crystal Structure Communications p. 2030 - 2032 (1999)
Update date:2022-08-04
Topics:
Neels, Antonia
Stoeckli-Evans, Helen
Plasseraud, Laurent
Garcia Fidalgo, Eva
Suess-Fink, Georg
The homologous title molecules, [Ru2Br4(C10H14) 2]·-C6H6, (1), and [Ru2I4(C10H14) 2]·C7H8, (2), consist of arene-ruthenium moieties [Ru-to-ring distances of 1.655 (2) A in (1) and 1.673 (3) A in (2)] with a terminal halogen ligand [Ru - Br 2.548 (1) A in (1) and Ru - I 2.726 (1) A in (2)], held together by two symmetrical halogen bridges [Ru - Br 2.575 (1) A in (1) and Ru - I 2.736 (1) A in (2)]. The arene rings are planar and parallel to each other, and the terminal halogen ligands are coordinated to ruthenium trans with respect to each other. Both molecules possess Ci symmetry.
Hubei Lingsheng Pharmaceuticals Co., Ltd.
Contact:+86-0710-3538058
Address:Xiangyang City Xiangcheng Economic Development Zone, Hubei Province
Chengdu Yunyi International Trade Co., Ltd
Contact:
Address:china
JiYi Chemical (Beijing) Co., Ltd.
Contact:+86-10-89385733
Address:Shilou Town of Fangshan District, Beijing
Guangzhou Puho Pharmaceutical Technology Co. Ltd.
Contact:86-20-29848035/29848075
Address:No.166, Chaoyang East Road, Panyu District, Guangzhou City, Guangdong Province
Melone Pharmaceutical Co., ltd
Contact:+86-411 82593920, 82593631
Address:No 232, JInma Roda, Development Zone, Dalian, China
Doi:10.1039/c29710001506
(1971)Doi:10.1055/s-1999-3174
(1999)Doi:10.1021/ic990631y
(2000)Doi:10.1016/S0277-5387(99)00300-9
(1999)Doi:10.1248/cpb.52.1105
(2004)Doi:10.1002/(SICI)1522-2675(19991215)82:12<2260::AID-HLCA2260>3.0.CO;2-Z
(1999)